Lupus and pregnancy

Obstetrical and Gynecological Survey

Volumn 66, Issue 10, 2011, Pages 639-653

  Baer, Alan N ^a   Witter, Frank R ^a   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DALTEPARIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FUROSEMIDE; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LA ANTIBODY; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE; RITUXIMAB; RO ANTIBODY; WARFARIN;

ACUTE FATTY LIVER OF PREGNANCY; ARTERY DISEASE; AUTOIMMUNE DISEASE; B LYMPHOCYTE DEPLETION; CATASTROPHIC ANTIPHOSPHOLIPID ANTIBODY SYNDROME; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; CONGENITAL MALFORMATION; CONTRACEPTION; CRANIOFACIAL MALFORMATION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG MEGADOSE; DUCTUS ARTERIOSUS CONSTRICTION; EAR MALFORMATION; ECHOCARDIOGRAPHY; ECHOGRAPHY; FACE DYSMORPHIA; FAMILY PLANNING; FATTY LIVER; FEMALE FERTILITY; FETUS DISEASE; FETUS ECHOGRAPHY; FETUS HEART BLOCK; FETUS HEMATOPOIESIS; FETUS LUNG MATURATION; FETUS MALFORMATION; FETUS WASTAGE; HEART BLOCK; HELLP SYNDROME; HEMATOPOIESIS; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; LABORATORY TEST; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; M MODE ECHOCARDIOGRAPHY; MATERNAL HYPERTENSION; NEPHROTOXICITY; NEUROLOGIC DISEASE; OROFACIAL CLEFT; PATHOPHYSIOLOGY; PATIENT COUNSELING; PATIENT MONITORING; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PREGNANCY OUTCOME; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PUERPERIUM; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

COUNSELING; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRE-ECLAMPSIA; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PRENATAL CARE; RISK ASSESSMENT;

EID: 83055178820     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e318239e1ee     Document Type: Review

References (117)

1. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277. (Pubitemid 13221242)
3. Domsic RT, Ramsey-Goldman R, Manzi S. Epidemiology and classification of systemic lupus erythematosus. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. 4th ed. Philadelphia, PA: Mosby Elsevier; 2008:1211-1216.
4. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006; 85:147-156. (Pubitemid 43833013)
5. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol. 2005;32:1709-1712. (Pubitemid 41324808)
6. Clowse ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127.e1-e6.
7. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:899-907.
8. Molad Y, Borkowski T, Monselise A, et al. Maternal and fetal outcome of lupus pregnancy: a prospective study of 29 pregnancies. Lupus. 2005;14:145-151. (Pubitemid 40327665)
9. Doria A, Tincani A, Lockshin M. Challenges of lupus pregnancies. Rheumatology (Oxford). 2008;47(suppl 3):iii9-12.
10. Lockshin MD, Reinitz E, Druzin ML, et al. Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med. 1984;77:893-898. (Pubitemid 15204870)
11. Mintz G, Niz J, Gutierrez G, et al. Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach. J Rheumatol. 1986;13:732-739. (Pubitemid 16015638)
12. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. 1991;34:1538-1545.
13. Urowitz MB, Gladman DD, Farewell VT, et al. Lupus and pregnancy studies. Arthritis Rheum. 1993;36:1392-1397. (Pubitemid 23304209)
14. Tandon A, Ibanez D, Gladman DD, et al. The effect of pregnancy on lupus nephritis. Arthritis Rheum. 2004;50:3941-3946. (Pubitemid 39643942)
15. Wong CH, Chen TL, Lee CS, et al. Outcome of pregnancy in patients with systemic lupus erythematosus. Taiwan J Obstet Gynecol. 2006;45:120-123.
16. Ruiz-Irastorza G, Lima F, Alves J, et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol. 1996;35:133-138.
17. van den Broe NR, Letsky EA. Pregnancy and the erythrocyte sedimentation rate. BJOG. 2001;108:1164-1167. (Pubitemid 33052480)
18. World Health Organization. Prevention and management of severe anaemia in pregnancy: report of a technical working group. 2008(December 13):38.
19. Burrows RF, Kelton JG. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med. 1988;319:142-145.
20. Lima F, Buchanan NM, Khamashta MA, et al. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum. 1995;25:184-192. (Pubitemid 26001344)
21. Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192:1897-1904. (Pubitemid 40827062)
22. Clowse ME, Magder LS, Witter F, et al. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52:514-521. (Pubitemid 40216315)
23. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol. 2003;16:161-167. (Pubitemid 37304071)
24. Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5:2060-2068.
25. Petri M. The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin North Am. 2007;33:227-235, v. (Pubitemid 46722668)
26. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus. 2008;17:416-420. (Pubitemid 351798719)
27. Clark CA, Spitzer KA, Nadler JN, et al. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol. 2003;30:2127-2132. (Pubitemid 37221840)
28. Clowse ME, Magder LS, Witter F, et al. Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006;107(2 Pt 1): 293-299.
29. Hayslett JP. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol. 1992;28:199-204. (Pubitemid 23044830)
30. Yasmeen S, Wilkins EE, Field NT, et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med. 2001;10:91-96.
31. Huong DL, Wechsler B, Vauthier-Brouzes D, et al. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis. 2001;60:599-604. (Pubitemid 32493987)
32. Julkunen H, Kaaja R, Palosuo T, et al. Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand. 1993;72:258-263. (Pubitemid 23265621)
33. Moroni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis. 2002;40:713-720.
34. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus. 2006;15:148-155.
35. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol. 1998;25:1526-1530. (Pubitemid 28364757)
36. Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum. 2001; 44:1832-1835. (Pubitemid 32758230)
37. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658-1666. (Pubitemid 28273312)
38. Gordon P, Khamashta MA, Rosenthal E, et al. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480-2487. (Pubitemid 39603101)
39. Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am. 2007;33:267-285, vi. (Pubitemid 46710331)
40. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69:1827-1830.
41. Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008;17:412-415. (Pubitemid 351798718)
42. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum. 2002;47:202-209. (Pubitemid 34303848)
43. Smith-Bouvier DL, Divekar AA, Sasidhar M, et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med. 2008;205:1099-1108. (Pubitemid 351679685)
44. Magid MS, Kaplan C, Sammaritano LR, et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998;179:226-234. (Pubitemid 28394500)
45. Abramowsky CR, Vegas ME, Swinehart G, et al. Decidual vasculopathy of the placenta in lupus erythematosus. N Engl J Med. 1980;303:668-672. (Pubitemid 10053702)
46. Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17:405-411. (Pubitemid 351798717)
47. Lynch AM, Murphy JR, Byers T, et al. Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am J Obstet Gynecol. 2008; 198:385.e1-e9.
48. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol. 2008;77:51-56.
49. Tseng CE, Buyon JP. Neonatal lupus syndromes. Rheum Dis Clin North Am. 1997;23:31-54. (Pubitemid 27089254)
50. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006;5:269-272. (Pubitemid 44269020)
51. Boumpas DT, Austin HA III, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-369. (Pubitemid 23310085)
52. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992; 116:488-498.
53. Huong DL, Amoura Z, Duhaut P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol. 2002;29:2571-2576. (Pubitemid 35416964)
54. Dooley MA, Nair R. Therapy insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol. 2008;4:250-257. (Pubitemid 351638682)
55. Oktay K, Sonmezer M, Oktem O, et al. Absence of conclusive evidence for the safety and efficacy of gonadotropinreleasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist. 2007;12: 1055-1066. (Pubitemid 350007017)
56. Mersereau J, Dooley MA. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Rheum Dis Clin North Am. 2010;36:99-108, viii.
57. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology (Oxford). 2008;47:1506-1509.
58. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91:3885-3890. (Pubitemid 44536859)
59. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000;43:550-556. (Pubitemid 30394945)
60. Huong DL, Wechsler B, Vauthier-Brouzes D, et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. Semin Arthritis Rheum. 2002;32:174-188. (Pubitemid 36043716)
61. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92:1803-1810.
62. Schwarz EB, Manzi S. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum. 2008;59:863-866. (Pubitemid 351847570)
63. Yazdany J, Trupin L, Kaiser R, et al. Contraceptive counseling and use among women with systemic lupus erythematosus: a gap in health care quality? Arthritis Care Res (Hoboken). 2011; 63:358-365.
64. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol. 2009;114(2 Pt 1):341-353.
65. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2539-2549. (Pubitemid 41785891)
66. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550-2558. (Pubitemid 41785892)
67. Chabbert-Buffet N, Amoura Z, Scarabin PY, et al. Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception. 2011;83: 229-237.
68. Petri M. Pregnancy in systemic lupus erythematosus and neonatal lupus. In: Hochberg MC, Silman AJ, Smolen JS, et al, eds. Rheumatology. 4th ed. Philadelphia, PA: Mosby Elsevier; 2008:1335-1339.
69. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33:237-252, v. (Pubitemid 46710328)
70. Chamber CD, Johnson DL, Jones KL, et al. Pregnancy outcome in women exposed to leflunomide: the OTIS autoimmune diseases in pregnancy project. Arthritis Rheum. 2006; 54(suppl 9):513.
71. Clowse ME. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheumatol. 2010;24:373-385.
72. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011.
73. Meadows M. Pregnancy and the drug dilemma. FDA Consum. 2001;35:16-20.
74. Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640-3647. (Pubitemid 44737176)
75. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebocontrolled study. Lupus. 2001;10:401-404. (Pubitemid 32578614)
76. Clowse ME, Magder LS, Witter F, et al. Azathioprine use in lupus pregnancy. Arthritis Rheum. 2005;52(suppl 9):S386-S387.
77. Ostensen M, Khamashta M, Lockshin M, et al. Antiinflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.
78. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun. 2009;33:92-98.
79. Empson M, Lassere M, Craig J, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005: CD002859.
80. Witter FR. Management of the high-risk lupus pregnant patient. Rheum Dis Clin North Am. 2007;33:253-265, v-vi. (Pubitemid 46710329)
81. Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol. 2006;20:685-694. (Pubitemid 44350114)
82. Christopher-Stine L, Petri M, Astor BC, et al. Urine proteinto-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol. 2004;31:1557-1559. (Pubitemid 39006637)
83. Witter FR, Petri M. Antenatal detection of intrauterine growth restriction in patients with systemic lupus erythematosus. Int J Gynaecol Obstet. 2000;71:67-68.
84. Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008;178:701-711. (Pubitemid 351441471)
85. Ruiz-Irastorza G, Khamashta MA. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2009;23: 575-582.
86. Papageorghiou AT, Leslie K. Uterine artery Doppler in the prediction of adverse pregnancy outcome. Curr Opin Obstet Gynecol. 2007;19:103-109. (Pubitemid 46412097)
87. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45:332-338. (Pubitemid 43372850)
88. Tincani A, Bompane D, Danieli E, et al. Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15:156-160.
89. Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999;8:677-684. (Pubitemid 29520535)
90. Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum. 1989;32:665-670. (Pubitemid 19179244)
91. Branch DW. Physiologic adaptations of pregnancy. Am J Reprod Immunol. 1992;28:120-122. (Pubitemid 23044810)
92. Buyon JP, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992;35:55-61.
93. Baines MG, Millar KG, Mills P. Studies of complement levels in normal human pregnancy. Obstet Gynecol. 1974;43:806-810.
94. Steegers EA, von Dadelszen P, Duvekot JJ, et al. Preeclampsia. Lancet. 2010;376:631-644.
95. Qazi U, Lam C, Karumanchi SA, et al. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol. 2008;35: 631-634. (Pubitemid 351500058)
96. Sanchez-Ramos L, Jones DC, Cullen MT. Urinary calcium as an early marker for preeclampsia. Obstet Gynecol. 1991;77: 685-688.
97. Chen HH, Lin HC, Yeh JC, et al. Renal biopsy in pregnancies complicated by undetermined renal disease. Acta Obstet Gynecol Scand. 2001;80:888-893.
98. Gomez-Puerta JA, Cervera R, Espinosa G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007;66:740-746. (Pubitemid 46846692)
99. Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33:196-205.
100. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116:4060-4069.
101. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355-377. (Pubitemid 33070843)
102. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169:1000-1006. (Pubitemid 23317544)
103. Hamasaki K, Mimura T, Kanda H, et al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report and literature review. Clin Rheumatol. 2003;22: 355-358. (Pubitemid 37483638)
104. Asherson RA, Galarza-Maldonado C, Sanin-Blair J. The HELLP syndrome, antiphospholipid antibodies, and syndromes. Clin Rheumatol. 2008;27:1-4. (Pubitemid 350182670)
105. Lockshin MD, Sammaritano LR. Lupus pregnancy. Autoimmunity. 2003;36:33-40. (Pubitemid 36321906)
106. Petri M. Pregnancy in SLE. Baillieres Clin Rheumatol. 1998; 12:449-476. (Pubitemid 28488243)
107. Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003;67:968-970. (Pubitemid 38018036)
108. Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747-756.
109. Systemic lupus erythematosus in pregnancy. Ann Intern Med. 1981;94:667-677.
110. Clowse ME, Magder L, Petri M. Cyclophosphamide for lupus during pregnancy. Lupus. 2005;14:593-597. (Pubitemid 41296995)
111. Kart Koseoglu H, Yucel AE, Kunefeci G, et al. Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus. 2001;10:818-820. (Pubitemid 34007897)
112. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth. 2009;9:8.
113. Martin JN Jr, Bailey AP, Rehberg JF, et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol. 2008;199:98-104.
114. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;62:1147-1152.
115. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010;62:1138-1146.
116. Jaeggi ET, Fouron JC, Silverman ED, et al. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation. 2004;110:1542-1548. (Pubitemid 39297974)
117. Witter FR, Zimmerman AW, Reichmann JP, et al. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol. 2009;201:553-559.